UY35545A - Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación - Google Patents
Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulaciónInfo
- Publication number
- UY35545A UY35545A UY0001035545A UY35545A UY35545A UY 35545 A UY35545 A UY 35545A UY 0001035545 A UY0001035545 A UY 0001035545A UY 35545 A UY35545 A UY 35545A UY 35545 A UY35545 A UY 35545A
- Authority
- UY
- Uruguay
- Prior art keywords
- procedures
- coag
- ulation
- compositions
- factory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
En el presente documento se proporcionan conjugados para inducir tolerancia de la proteína factor de coagulación, en el que el conjugado comprende una proteína factor de coagulación o un fragmento antigénico o variante del mismo y un ligando Siglec. También se proporcionan composiciones farmaceúticas, procedimientos y kits que comprenden los conjugados.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361816790P | 2013-04-28 | 2013-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35545A true UY35545A (es) | 2014-11-28 |
Family
ID=50846907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035545A UY35545A (es) | 2013-04-28 | 2014-04-28 | Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160279252A1 (es) |
EP (1) | EP2991684B1 (es) |
JP (1) | JP2016519120A (es) |
CN (1) | CN105451774A (es) |
AR (1) | AR096123A1 (es) |
CA (1) | CA2910277A1 (es) |
ES (1) | ES2691041T3 (es) |
HK (1) | HK1217167A1 (es) |
TW (1) | TW201519900A (es) |
UY (1) | UY35545A (es) |
WO (1) | WO2014179184A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160060324A1 (en) * | 2013-04-22 | 2016-03-03 | James C. Paulson | Methods and Compositions for Treating Bleeding Disorders |
DK3458085T3 (da) | 2016-05-20 | 2023-01-30 | Octapharma Ag | Glykosyleret vwf-fusionsproteiner med forbedret farmakokinetik |
CN108926719B (zh) * | 2017-05-25 | 2020-09-01 | 北京格瑞特森生物医药科技有限公司 | 用c(RGD-ACP-K)修饰的长循环脂质体 |
WO2018225873A1 (ja) * | 2017-06-09 | 2018-12-13 | 協和発酵キリン株式会社 | 核酸含有ナノ粒子 |
EP3839059A1 (en) * | 2019-12-16 | 2021-06-23 | CGT Enterprises, LLC | Devices and methods for determining coagulation factor activities |
WO2024015872A2 (en) * | 2022-07-13 | 2024-01-18 | Osprey Biopharmaceuticals, Inc. | Autoantigens engineered to suppress autoimmune response |
CN116036244B (zh) * | 2023-02-24 | 2023-09-19 | 北京基科晟斯医药科技有限公司 | 培重组人凝血因子VIII-Fc融合蛋白用于治疗含抑制物的血友病A的用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1694274B1 (en) * | 2003-12-03 | 2013-04-24 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
WO2005055950A2 (en) * | 2003-12-03 | 2005-06-23 | Neose Technologies, Inc. | Glycopegylated factor ix |
US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
EP2371856B1 (en) * | 2004-11-12 | 2022-05-18 | Bayer HealthCare LLC | Site-directed modification of FVIII |
CA2625999A1 (en) * | 2005-10-17 | 2007-04-26 | Health Research, Inc. | Specific acceptors for transferases to saccharides and method for obtaining and using same |
US20120164130A1 (en) * | 2009-07-31 | 2012-06-28 | Bayer Healthcare Llc | Modified Factor IX Polypeptides and Uses Thereof |
-
2014
- 2014-04-25 TW TW103115001A patent/TW201519900A/zh unknown
- 2014-04-27 WO PCT/US2014/035590 patent/WO2014179184A1/en active Application Filing
- 2014-04-27 ES ES14727380.9T patent/ES2691041T3/es active Active
- 2014-04-27 JP JP2016510820A patent/JP2016519120A/ja active Pending
- 2014-04-27 CA CA2910277A patent/CA2910277A1/en not_active Abandoned
- 2014-04-27 EP EP14727380.9A patent/EP2991684B1/en not_active Not-in-force
- 2014-04-27 CN CN201480032984.XA patent/CN105451774A/zh active Pending
- 2014-04-27 US US14/787,444 patent/US20160279252A1/en not_active Abandoned
- 2014-04-28 UY UY0001035545A patent/UY35545A/es not_active Application Discontinuation
- 2014-04-28 AR ARP140101748A patent/AR096123A1/es unknown
-
2016
- 2016-04-27 HK HK16104791.5A patent/HK1217167A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2991684A1 (en) | 2016-03-09 |
WO2014179184A8 (en) | 2015-10-29 |
EP2991684B1 (en) | 2018-07-11 |
TW201519900A (zh) | 2015-06-01 |
CA2910277A1 (en) | 2014-11-06 |
WO2014179184A1 (en) | 2014-11-06 |
CN105451774A (zh) | 2016-03-30 |
AR096123A1 (es) | 2015-12-09 |
ES2691041T3 (es) | 2018-11-23 |
HK1217167A1 (zh) | 2016-12-30 |
US20160279252A1 (en) | 2016-09-29 |
JP2016519120A (ja) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35545A (es) | Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación | |
FR21C1030I2 (fr) | Conjugué anticorps anti-her2-médicament | |
MA52669A (fr) | Conjugués peptidiques de camptothécine | |
CO2019005966A2 (es) | Esteroides y conjugados de proteínas de los mismos | |
DOP2018000259A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
CO2018005525A2 (es) | Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab | |
BR112016025291A2 (pt) | conjugados de anticorpo anti-ptk7-fármaco | |
UY36186A (es) | Ácidos grasos novedosos y su uso en la conjugación con biomoléculas | |
CY1124425T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης | |
BR112019004785A2 (pt) | variantes de alfa-glicosidase ácida e usos das mesmas | |
PE20150892A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
PE20150646A1 (es) | Metodos de tratamiento de una tauopatia | |
CR20150626A (es) | Anticuerpos frente a ácidos teicoicos de pared y conjugados | |
UY4236Q (es) | Configuración aplicada en zapato | |
CY1124521T1 (el) | Σκευασματα αντισωματος anti-cd19 | |
BR112019004783A2 (pt) | variantes de alfa-glicosidase ácida e usos das mesmas | |
BR112015021880A2 (pt) | rearranjo de vírus influenza b | |
BR112016019389A8 (pt) | Vacina, e, peptídeo | |
DK3666787T3 (da) | Antistoflægemiddelkonjugater som inkluderer hemiasterlinderivat | |
CO2017007316A2 (es) | Formulación farmacéutica | |
CR20160495A (es) | Composiciones libres de células para la restauración de células y métodos para la preparación y utilización de las mismas | |
UY4314Q (es) | Configuracion aplicada en zapato | |
CY1118277T1 (el) | Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης | |
NI201600061A (es) | Formulaciones de inyección con base en aceite de sésamo | |
UY4233Q (es) | Configuración aplicada en zapato |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20211206 |